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Summary 
A  first  or dominant immunization with one antigen markedly inhibited specific cytolytic T 
lymphocyte (CTL) responses  to a second unrelated aUoantigen without suppressing antibody 
responses  to other antigens. Suppression  was induced rapidly, became systemic,  and could be 
transferred passively with only serum. Suppression did not result from elimination of cells capable 
of responding to the second antigen. The mechanisms responsible for this "priority of the first 
response" may be the same that help protect the fetus during pregnancy, promote renal allograft 
survival after multiple blood transfusions, and prevent effective CTL-mediated immunity to variants 
of tumor cells or infectious agents that arise during tumor progression or chronic infections. 
jection of immunogenic tumors or elimination of var- 
ious parasitic and viral infections depends ultimately 
on  CD8 §  CTL  directed  against  tumor  or  infected cells. 
Variants,  however,  may arise that express new or modified 
antigenic epitopes to which the host fails to respond. The 
molecular mechanism for generation of variants and escape 
from effective immunity has been described for various para- 
sitic infections; in other diseases variants probably arise most 
frequently from mutations in malignant cells or in viruses, 
as may occur in an individual during chronic infection with 
HIV or in an infected population during epidemics of  influenza 
(1-4).  Interestingly, the host in which a variant arises may 
respond with high antibody titers to unrelated antigens (5), 
and the variant, though failing to induce immunity in the 
host of origin, is immunogenic in a normal individual (6-8). 
We report here development of a murine model for studying 
why variant tumor cells or infectious agents may fail to in- 
duce effective CTL-mediated immunity in an original host. 
Materials and Methods 
Mice and Cell Lines.  C3H/HeN (MTV-) females were par- 
chased from the Frederick Cancer Research Production Facility 
(Frederick, MD). Mice were housed in a barrier facility and fed 
sterile water and food. Mice were 8-12 wk old when used ex- 
perimentally. P815, EL4, and 1591-RE cell lines grown in MEM 
supplemented with  10%  FCS were monitored  regularly to be 
mycoplasma free. For convenience  of presentation, C3H or 1591- 
RE tumor cells bearing H2  k are referred to as A, C57BL or EL-4 
tumor cells bearing H2  b as t3, and BALB/c or P815 cells bearing 
H2  a as C. 
Immunizations.  Recipients  under light ether anesthesia were in- 
jected in hind foot pads with 0.05 ml of cell suspension. Cells for 
immunization were dispersed  washed allogeneic  spleen cells, xeno- 
geneic horse or sheep erythrocytes (HRBC or SRBC), or 1591-R.E 
tumor cells harvested from tissue culture. Washed cells were sus- 
pended in sterile HBSS. 
Assay.for Cytotoxic Cells.  Each  popliteal lymph node and spleen 
was assayed separately in triplicate; in addition, for most experi- 
ments cells pooled from identically treated mice were also assayed 
in triplicate. CTL were measured  using a 4-h SlCr release assay  (9); 
each cell suspension was assayed at eight double dilutions begin- 
ning with an E/T cell ratio of 100:1; for ease of comparing differ- 
ently treated groups we have recorded results for only three four- 
fold dilutions. Each number recorded is the percent 51Cr release 
and is the mean for nine separate determinations; results for pooled 
cells are not recorded since at each  dilution these results were within 
one dilution, plus or minus, of the number recorded. CTL in one 
way MLC were assayed  similarly; each result is the mean for tripli- 
cate cultures assayed separately; the procedures for MLC and the 
preparation of nonadherent cells and dendritic cells (DC) 1 are de- 
scribed in the accompanying manuscript (10). 
We have repeatedly  confirmed that CTL present in lymph nodes 
or spleens of mice immunized as described above  or recovered from 
MLC are CD8 +, i.e., treating the cells with ceCD8 antibody and 
complement virtually eliminates cytolytic activity against appro- 
priate target cells; also, the cells had very low cytotoxicity against 
YAC-1, a usual target for measuring NK activity (11). These results 
are not recorded since cytotoxicity reported for control target cells 
in the following experiments sets an appropriate value for com- 
paring cytotoxicity against specific target cells. 
Results 
Preliminar  7  Observations.  The  model developed  for the 
present studies was derived from observations using an im- 
1 Abbreviation used in this paper: DC, dendritic cell. 
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tion into syngeneic mice grows initially but is subsequently 
rejected by  the  vast  majority  of mice;  rejection requires 
CD8 + lymphocytes directed against a dominant class I al- 
loantigen of unknown origin (4).  Very occasionally 1591 
tumors grow progressively, but when this occurs tumors no 
longer express the dominant antigen, although other antigens 
are still expressed. For example, a variant of 1591 designated 
PRO4L grows progressively in normal mice challenged with 
107 to  108  tumor cells, but is rejected by mice challenged 
with 106 tumor cells. Rejection of PRO4L is still dependent 
on CD8 + lymphocytes, but by lymphocytes recognizing a 
different antigen (4). 
Possibly  a first response to 1591 suppressed effective im- 
munity and permitted outgrowth of PRO4L in the original 
host. This notion was supported in an experiment showing 
that no tumors grew progressively in six of six mice injected 
with 107 1591 tumor cells or in six of six mice injected with 
106 PKO4L tumor cells, but PRO4L tumors grew progres- 
sively in four of seven mice injected with a mixture of these 
numbers of tumor cells. Furthermore, mice injected several 
times with 1591 tumor cells alone failed to mount appreciable 
CTL responses to allogeneic spleen cells mixed with the tumor 
cells for subsequent injections (D. A. Rowley, unpublished 
results). These observations led to experiments that were de- 
signed to test the general possibility that a first or dominant 
immunization suppressed CTL responses to unrelated alloan- 
tigens. Because allogeneic cells were more readily available 
in large numbers and could be prepared in a more standardized 
way than tumor cells, they were used for the following ex- 
periments. 
To  approximate  continuous  antigenic  stimulation  of a 
tumor, allogeneic cells were injected every 2 or 3 d; in some 
experiments the numbers of cells were increased exponen- 
tially for the first two or three injections to mimic increasing 
antigenic challenge of growing tumors. Allogeneic cells were 
injected in a hind foot pad; CTL were measured in draining 
popliteal lymph nodes and spleens  1 or 2 d after the last in- 
jection of antigen. Elevated CTL responses occurred after three 
injections, i.e., 7-10 d after injections were begun. Levels of 
CTL activity fell rapidly t>4 d after injections were stopped. 
CTL responses to three or four repeated injections were much 
higher than to the same dose of allogeneic cells given as a 
single dose 7 or 9 d earlier.  CTL appeared at higher levels 
earlier in draining lymph nodes but responses were equiva- 
lent in lymph nodes and spleens after four or more injections 
of allogeneic cells.  The  mixing of two  antigens did not 
diminish the CTL responses to either antigen and neither 
antigen stimulated significant responses to the other antigen 
(Fig.  1). The absence of crossreactions or competition per- 
sisted for at least eight injections given over 21 d, the longest 
interval tested. These results and those recorded in the fol- 
lowing figures and table have been confirmed in two or more 
comparable experiments. 
A First or Dominant Immunization Suppressed CTL to a Second 
Antigen.  When mice that had received two or three injec- 
tions of B cells were challenged with a mixture of B and 
C cells, CTL responses to C were very low; suppression to 
C was systemic since it did not matter whether the second 
antigen was mixed with the first antigen or was injected in 
the contralateral foot (Fig. 2). In other experiments, we found 
that the phenomenon was reproducible regardless of which 
strain of mouse was used as responders and which allogeneic 
cells were used as the first and second antigens. Also,  sup- 
pression persisted for as long as injections of the first antigen 
were continued, 21 d being the longest time tested. 
An interval between beginning the first and second im- 
munizations was not necessary for establishing priority if one 
antigen was made dominant initially by dosage of antigen 
(Fig. 3, Exp. 1), Also, interaction between the cells used for 
immunization did not contribute to suppression, since a first 
immunization with B or C abolished responses to the other 
alloantigen  when  F1  cells  (cells  from  CB6  female mice, 
which were offspring of BALB/c male  x  C57 female) were 
used as the source of the second antigen (Fig.  3,  Exp.  2). 
Suppression of CTL but Not of  Antibody Responses.  A first 
immunization that so effectively suppressed CTL responses 
did not suppress antibody responses to xenogeneic erythro- 
cytes used as a second antigen. For example, mice were in- 
jected three times with B spleen cells, as in the experiment 
in Fig. 2; three mice per group were then injected twice at 
2-d  intervals  with  a  mixture  containing  10  v B  and  10  8 
SRBC,  10  v B  and  107  C  cells,  or  10  v B,  107  C,  and  108 
SRBC per injection; controls included three additional groups 
not preinjected with B but receiving these injections. CTL 
responses to B and plaque-forming cells (PFC) to SRBC (12) 
were measured 4 and 6 d after the first injections of SRBC. 
All mice injected with SRBC had equivalent numbers of PFC: 
6,000-10,000  direct (IgM) PFC and <1,000 indirect (IgG) 
PFC per node or spleen at day 4, and 20,000-60,000 indirect 
PFC per lymph node or spleen on day 6. All mice receiving 
the initial three injections of B had equivalent CTL responses 
to B. 
In contrast, mice preinjected three times at 2-d intervals 
with xenogeneic erythrocytes failed to respond with CTL 
to allogeneic cells. For example, in one experiment mice were 
injected three times at 2-d intervals with a mixture containing 
10  s SKBC and 10  s HRBC;  the mice were then challenged 
three more times with a mixture containing 2 x  108 RBC 
and 10  v C  cells.  1 d after the last (7 d after the first)  injec- 
tion of C cells the mean CTL response of mice preinjected 
with RBC was 13, 7, and 5% lysis of C target cells at E/T 
ratios of 100:1, 25:1, and 6:1, respectively; the mean response 
of non-preinjected controls was 40, 20, and 11% lysis of C 
target cells at the same E/T  ratios. 
Cells from  Suppressed Mice Respond Normally  in  Culture. 
Cells were obtained from spleens and lymph nodes of mice 
1 or 2 d after the mice had received three or four injections 
of a first antigen; i.e.,  at a time when mice would not re- 
spond with CTL when challenged with a second antigen. 
The cells from such mice invariably responded to a second 
antigen in MLC as well as control cells from normal mice; 
also, cells from mice injected first with one antigen followed 
by injection of a mixture of the first and second antigen 
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Figure  1.  Absence of crossreaction or competition 
between alloantigens. 
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Figure 2.  Prior immunization with allogeneic lymphoid cells prevents a CTL response locally  and systemically to subsequent simultaneous immuniza- 
tion with unrelated allogeneic lymphoid cells. Antigen B was injected into right hindfoot pads. Antigen C was mixed with antigen B, group 2; antigen 
C was injected separately into left hind foot pads groups 3 and 4. Anti-B CTL are recorded for right popliteal lymph nodes, Groups 1, 2, and 3 and 
for left popliteal lymph nodes for group C. Anti-C CTL are recorded for right popliteal lymph nodes, groups 1 and 2, and for left popliteal and for 
groups 3 and 4. 
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Figure 3.  Dominant or first immunization with 
one antigen prevents CTL responses to a second 
alloantigen. In the first experiment, antigen B was 
made dominant by dosage of cells; antigens B and 
C  were mixed,  group  1.  In experiment  2, B or 
C antigens were made dominant by first injection 
followed by injection of F1 cells. For both experi- 
ments injections were in right foot pads and the 
responses recorded  are for right popliteal lymph 
nodes. 
responded normally to the second antigen in culture (e.g., 
Fig.  4,  Exp.  1). 
Conceivably, DC, which are required for CTL responses 
in cultures (11), might be altered by a first immunization; 
however, lymph nodes of mice injected with a first antigen 
or with a first antigen followed by a mixture of first and second 
antigen were as good a source of functional DC as normal 
spleens when tested using normal responder and irradiated 
stimulators cells, both depleted of DC (Fig.  4,  Exp.  2). 
Suppression by Passively Transferred  Sera.  In different experi- 
ments sera were obtained from A mice injected repeatedly 
with B or C  cells.  Normal A  mice injected with the sera 
were challenged with three injections of either 10  7 B or 10  7 
C  cells. Surprisingly, serum raised against B not only sup- 
pressed CTL responses to B but also to C, and similarly, serum 
raised against C suppressed responses to both antigens. The 
amount of serum required to suppress  CTL responses was 
quite large (0.5-1.0 ml whole serum per recipient); suppres- 
sion was usually not as marked (approximately fourfold) as 
with active immunization, but suppression by unrelated im- 
mune sera was consistent in five consecutive experiments. 
These findings, illustrated in a single experiment (Table  1, 
Exp. 1), show that normal serum given passively to A mice 
sensitized to B had no effect on CTL responses to C, while 
both anti-B and anti-C sera suppressed responses to C. This 
lack of specificity of suppression was also observed using serum 
from mice injected repeatedly with xenogeneic erythrocytes 
(Table  1,  Exp.  2). 
Discussion 
An extensive literature records that a first immunization 
with one antigen may suppress the antibody response to an- 
other antigen given subsequently (13-17).  Selection of com- 
peting antigens, dosages of antigen, and timing of injections 
were usually critical for observing "antigenic competition" 
which was attributed in different models to:  (a) consump- 
tion or exhaustion of critical cells or factors by the first im- 
munization; (b) induction or activation of nonantigen-specific 
regulatory cells such as NK cells (18, 19); or (c) feedback in- 
hibition by idiotypic or antiidiotypic antibody or effector cells 
directed against  the  suppressed  epitopes  or  present  on  a 
838  A First  or Dominant Immunization Gr 1 
Days 
O  2  4  6 
107B  107B  107B 
LN lymphocytes or DC 
Gr 2 
1  --  -""  ~  LN lyrnphocytes  or  DC 




>  splenic tymphocytes or DC 
Exp  I 
Irradiated 
Responder  Stimulator 
Lymphocyte  Cells 
%  51Cr  Release 
(z C CTL 
100:1  Z5:I  6:1 
Grl  +  C  70  52  34 
Gr 2  +  C  76  68  51 
Gr  3  +  C  75  71  61 
Exp  2 
DC 
Grl  + 
Gr2  + 
Cells  for  MLC 
49  36  24 
39  29  10 
Normal splenic A responder 
lymphocytes and irradiated 
normal splenic C stimulator 
cells,  both treated to 
Gr 3  +  eliminate  DC  57  43  31 
None  +  -  5  4  3 
Figure  4.  A first immunization with one alloantigen  does not reduce 
or eliminate lymphocytes (Exp. 1) or dendritic cells (Exp. 2) required for 
primary CTL responses to a different alloantigen  in vitro. 
common carrier (20-26).  In many of the models antibody 
responses were suppressed only moderately so that the biologi- 
cal significance of antigenic competition was often question- 
able. In contrast,  the conditions for inducing suppression of 
CD8 + CTL responses by a first or dominant immunization 
are not stringent and suppression  is often marked without 
affecting  antibody responses  to  a  second  antigen.  Suppres- 
sion is induced rapidly, becomes systemic early, can be pas- 
sively transferred using serum  from fully suppressed mice, 
and, as we report in the accompanying manuscript  (10),  is 
undoubtedly dependent on IgG. Suppression is inducible in 
two other strains of mice that have been tested and is inde- 
pendent  of the  combination  of antigens  used  (data  not 
reported), so that the phenomenon would appear to be general. 
Table  1.  Passive Transfer of Suppression by Sera 
Percent  SlCr release of C 
target  cells* 
Exp.  Sera*  100:1  25:1  6:1 
1  olB  18  5  2 
aC  6  1  1 
NMS  39  18  12 
None  39  16  12 
2  otRBC  31  16  6 
NMS  66  38  16 
* Normal A mice were immunized with 107 C cells injected every 2 d 
four times and killed on day 8.  Mice receiving  serum were given 0.6 
ml whole serum on day 0 and 0.3 ml on day 3 (one half intravenously 
and one half intraperitoneally  each time.) Results are the means for popliteal 
LN (three or four mice per group);  each LN was assayed in triplicate 
against  B  and C  target  cells;  the percent  stCr release for all samples 
against B  target cells was <10%  at E/T of 100:1. 
* Donors were A mice that received four injections of 107 B or C cells 
(Exp.  1)  or four  injections  of a mixture of 10  s  sheep and  10  s horse 
erythrocytes  (Exp.  2). Sera were given on the same day as donors were 
bled. 
It seems remarkable that this mechanism of nonantigen- 
specific suppression of CTL responses should exist, but in- 
terestingly,  a maternal antibody response  to paternal HLA 
occurs early in pregnancy and an absence of this response may 
be associated with spontaneous abortion during the first tri- 
mester (27-29).  Immunizing such women with paternal PBL 
may promote successful pregnancy (30-32).  Thus, an early 
maternal antibody response to paternal antigens expressed by 
the fetus may help prevent maternal CTL responses directed 
against  other antigens expressed later during fetal develop- 
ment. Operation of the same mechanism may explain why 
survival of renal aUografts is enhanced in patients who have 
received multiple blood transfusions or were intentionally im- 
munized with homologous erythrocytes (33, 34). On the other 
hand, the failure to develop CTL-mediated immunity to an- 
tigens expressed sequentially after a first or dominant immu- 
nization should be detrimental to individuals bearing immuno- 
genic  tumors  or  infected  with  organisms  that  give  rise  to 
variants expressing new or different antigenic epitopes. Thus, 
understanding how an early antibody response may suppress 
CTL responses to antigens subsequently expressed should help 
in developing new ways for promoting allograft survival and 
more  effective  immunity  to  variants. 
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